Clinical Trial Update: Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial results for intrathecal autologous mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Autologous mesenchymal stem cell-derived neural progenitors (MSC-NP) (mesenchymal stem cell-derived neural progenitors)

Snippet

Sponsor: Tisch Multiple Sclerosis Research Center of New York | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-06-11